Simple description

Products name: Cetilistat

Cetilistat is a new gastrointestinal lipase inhibitor, which was developed by Alizyme in the UK. Later, “Norgina BV” won the global agency of “Cetilistat”. In Japan, due to cooperation with Takeda Pharmaceuticals, Xinlishitar was approved as a drug for treating obesity in September 2013. The product name is “Oblian”. Neolistat is a long-term and powerful specific gastrointestinal lipase inhibitor. It plays a therapeutic role by forming a Covalent bond with the active serine site of gastric lipase and pancreatic lipase in the stomach and small intestine cavity to inactivate the enzyme. Inactive enzymes cannot hydrolyze the fat in food, mainly triglycerides, into absorbable free fatty acids and monoacylglycerols, and undigested triglycerides cannot be absorbed by the body, To reduce calorie intake and control weight.

Chinese name: Xinlishitar

Chinese alias: 2-hexadecyl oxy-6-methyl-4H-3,1-benzoxazine-4-one

English name: Cetilistat

English alias: 2- (Hexadecycloxy) -6-methyl-4H-3,1-benzoxazin-4-one; Cetilstat; 2-Hexadecycloxy-6-methyl-4H-3,1-benzoxazin-4-one;

CAS number: 282526-98-1

Molecular formula: C25H39NO3

Molecular weight: 401.58200

Precision quality: 401.29300

PSA: 52.33000

LogP: 7.35650

Physical and chemical properties

Appearance and properties: White or almost white powder

Density: 1.027g/cm3

Boiling point: 509.671? C at 760 mmHg

Flash point: 158.925? C

Refractive index: 1.521

Steam pressure: 0mmHg at 25 ° C





    Captcha Plus loading...